Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Giovanna Muscogiuri, Ralph A. DeFronzo, Amalia Gastaldelli, et al.
Trends in Endocrinology and Metabolism (2016) Vol. 28, Iss. 2, pp. 88-103
Closed Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 250
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Obesity as a risk factor for Alzheimer's disease: weighing the evidence
Susan Alford, Dhiren Patel, Nikolaos Perakakis, et al.
Obesity Reviews (2017) Vol. 19, Iss. 2, pp. 269-280
Open Access | Times Cited: 193
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 170
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Lærke S. Gasbjerg, Mads M. Helsted, Bolette Hartmann, et al.
Diabetes (2019) Vol. 68, Iss. 5, pp. 906-917
Open Access | Times Cited: 155
Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease
Jong Sung Park, Tae‐In Kam, Saebom Lee, et al.
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 130
Role of the gut–brain axis in energy and glucose metabolism
Hallie Wachsmuth, Savanna N. Weninger, Frank A. Duca
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 4, pp. 377-392
Open Access | Times Cited: 129
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 73
Hepatic glucose metabolism in the steatotic liver
Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 5, pp. 319-334
Closed Access | Times Cited: 32
Type 2 Diabetes Mellitus Exacerbates Pathological Processes of Parkinson's Disease: Insights from Signaling Pathways Mediated by Insulin Receptors
Shufen Liu, Tingting Liu, Jingwen Li, et al.
Neuroscience Bulletin (2025)
Closed Access | Times Cited: 2
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Leszek Szablewski
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 542-542
Open Access | Times Cited: 2
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Yoon Sin Oh, Hee‐Sook Jun
International Journal of Molecular Sciences (2017) Vol. 19, Iss. 1, pp. 26-26
Open Access | Times Cited: 152
Current and emerging avenues for Alzheimer's disease drug targets
Raúl Loera‐Valencia, Ángel Cedazo‐Mínguez, Paul-Ariel Kenigsberg, et al.
Journal of Internal Medicine (2019) Vol. 286, Iss. 4, pp. 398-437
Open Access | Times Cited: 118
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Therese S. Salameh, Elizabeth M. Rhea, Konrad Talbot, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114187-114187
Open Access | Times Cited: 106
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Lærke S. Gasbjerg, Natasha C. Bergmann, Signe Stensen, et al.
Peptides (2019) Vol. 125, pp. 170183-170183
Closed Access | Times Cited: 94
Dendrobium huoshanense polysaccharide regulates hepatic glucose homeostasis and pancreatic β-cell function in type 2 diabetic mice
Hongyan Wang, Qiang-Ming Li, Nianjun Yu, et al.
Carbohydrate Polymers (2019) Vol. 211, pp. 39-48
Closed Access | Times Cited: 90
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study
Francesco Vadini, Paola Simeone, Andrea Boccatonda, et al.
International Journal of Obesity (2020) Vol. 44, Iss. 6, pp. 1254-1263
Closed Access | Times Cited: 80
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
CarmenM Labandeira, Arturo Fraga-Bau, David Arias Ron, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 8, pp. 1652-1652
Open Access | Times Cited: 61
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 48
Liraglutide prevents high glucose induced HUVECs dysfunction via inhibition of PINK1/Parkin-dependent mitophagy
Yikai Zhang, Sheng‐Yao Wang, Xia Chen, et al.
Molecular and Cellular Endocrinology (2022) Vol. 545, pp. 111560-111560
Open Access | Times Cited: 43
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Ronald Goldenberg, Alice Cheng, Tess Fitzpatrick, et al.
Stroke (2022) Vol. 53, Iss. 5, pp. 1813-1822
Open Access | Times Cited: 39
Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes
Clara Luna-Marco, Arantxa Martinez de Marañon, Alberto Hermo-Argibay, et al.
Redox Biology (2023) Vol. 66, pp. 102849-102849
Open Access | Times Cited: 36
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy
Roshan Dhanapalaratnam, Tushar Issar, Alexandra T. K. Lee, et al.
Diabetologia (2024) Vol. 67, Iss. 3, pp. 561-566
Closed Access | Times Cited: 11
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function
Wenran Ren, Jianhui Chen, Wenjing Wang, et al.
Neuron (2024) Vol. 112, Iss. 6, pp. 972-990.e8
Open Access | Times Cited: 10
Gut–Brain Interactions and Their Impact on Astrocytes in the Context of Multiple Sclerosis and Beyond
Julia Zißler, Veit Rothhammer, Mathias Linnerbauer
Cells (2024) Vol. 13, Iss. 6, pp. 497-497
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top